CLYBL and focal segmental glomerulosclerosis: For adult patients, the guideline suggests CYC, calcineurin inhibitor (CSA or TAC), or MMF for frequently relapsing or steroid-dependent minimal change nephrotic syndrome (MCNS), CSA or MMF with high-dose dexamethasone for steroid-resistant focal segmental glomerulosclerosis (FSGS), and alkylating agent (CYC or CLB) or calcineurin inhibitor for idiopathic membranous nephropathy (IMN) resistant to initial therapy.